We next sought to explore the specific vulnerability of ETS1-high cancers by conducting an in silico screen based on the PRISM Primary Repurposing dataset24, in which 4,687 compounds were tested across 483 cancer cell lines with matched RNA-Seq data. This evidence concerns the gene ETS1 and cancer.